Towards Understanding the Aetiology and Pathophysiology of the Emetic Reflex: Novel Approaches to Antiemetic Drugs

Abstract

The introduction of 5-HT₃ antagonists, such as ondansetron, as antiemetic agents has transformed the management of patients receiving chemotherapy or radiation therapy. Studies in animal models with NK4 antagonists suggest that these represent a new class of antiemetic agents having a broader spectrum of activity than 5-HT₃ antagonists. Compounds of this class may prove to be more effective in man against delayed emesis induced by cisplatin, postoperative nausea and vomiting and motion sickness. Thus, they have the potential to complement 5-HT₃ antagonists and so provide a further advance in the management of nausea and vomiting.